Low frequency of HER2 amplification and overexpression in early onset gastric cancer

BACKGROUND: The recent ToGA trial results indicated that trastuzumab is a new, effective, and well-tolerated treatment for HER2-positive gastric cancer (GC). Although GC mainly affects older patients, fewer than 10% of GC patients are considered early-onset (EOGC) (presenting at the age of 45 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Moelans, Cathy B., Milne, Anya N., Morsink, Folkert H., Offerhaus, G. Johan A., van Diest, Paul J.
Formato: Texto
Lenguaje:English
Publicado: Springer Netherlands 2011
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063579/
https://www.ncbi.nlm.nih.gov/pubmed/21394646
http://dx.doi.org/10.1007/s13402-011-0021-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063579/
https://www.ncbi.nlm.nih.gov/pubmed/21394646
http://dx.doi.org/10.1007/s13402-011-0021-0

Ejemplares similares